MGMT promoter methylation as a predictive biomarker for response to radiotherapy versus chemotherapy in malignant astrocytomas in the elderly: The NOA-08 trial

Reporter: Annemarie Fernandes
The Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 3 de junio del 2012

Translation for this article does not exist


7 Tips for Giving Smart on #givingtuesday
by Christina Bach, MSW, LCSW, OSW-C
November 25, 2015

Related News

Surgery for Spinal Metastasis Up From 2000 to 2009 in U.S.

Sep 2, 2014

In-hospital mortality rates, length of stay steady, but complications, costs up

Death Rate for All Cancers Down in U.S. From 2000 to 2009

Jan 8, 2013

Incidence of cancers down for men, stabilized in women; incidence of some cancers increasing

AACR: Markers Hint at Who Cancer Treatments Could Help

Nov 28, 2015

Meeting at cancer conference discusses possible role of TIMP-1, Trim62, CYP2D6 phenotype